## Does Paradromics Have the Clinical Leadership to Take Connexus Beyond First-in-Human?

[Paradromics](https://bciintel.com/companies/paradromics) has appointed William J. Marks, Jr., MD, MS-HCM, as Chief Clinical Officer, bringing nearly three decades of implantable neuromodulation and clinical science experience to a company that completed its first human implantation of the [Connexus](https://bciintel.com/glossary/connexus) BCI just weeks before this announcement. Marks arrives from Verily Life Sciences, where he served in senior clinical leadership roles — including Head of Clinical Neurology and Head of Clinical Science — from 2016 to 2023. Before that, he spent nearly two decades as Professor of Neurology at UCSF and served as Consultant Medical Director for [Medtronic Neuromodulation](https://bciintel.com/companies/medtronic-neuro)'s global [Deep Brain Stimulation](https://bciintel.com/glossary/dbs) business from 2004 to 2010.

The hire is specifically timed to support the FDA-approved Connect-One Early Feasibility Study of the Connexus BCI, being conducted at University of Michigan Health. That study is evaluating long-term use of the device to restore speech and enable computer control for people with severe motor impairment — the primary target population being those living with advanced motor neuron disease, including [Amyotrophic Lateral Sclerosis (ALS)](https://bciintel.com/glossary/als).

Marks will serve as Paradromics' full-time internal clinical lead, overseeing clinical strategy, regulatory planning, product development alignment, and the company's roadmap for new indications.

**The short answer:** This hire signals Paradromics is transitioning from an engineering-first startup into a clinical-stage medical device company — a necessary evolution if the Connexus BCI is to move from feasibility data to a PMA submission.

---

## What Marks Brings That Paradromics Needed

The profile here matters. Marks has direct, hands-on experience with Class III implantable device development through his Medtronic DBS work — exactly the regulatory category the Connexus BCI will eventually need to navigate for a premarket approval. His seven years at Verily added large-scale clinical science infrastructure experience, specifically building cross-functional clinical research teams in a technology company context. That dual background — traditional medical device regulatory pathways plus tech-company clinical operations — is precisely what a BCI company at Paradromics' stage requires.

He is also co-founder, General Partner, and Chief Medical Officer of Nexus NeuroTech Ventures, a neurotechnology investment firm focused on neurological health companies. That background gives him a capital-markets lens that will be useful as Paradromics builds the clinical evidence package needed to attract the next funding round and potential strategic partners.

His academic credentials reinforce the clinical credibility play: BS from Marquette University, MD from Johns Hopkins University School of Medicine, neurology residency and epilepsy/clinical neurophysiology fellowship at UCSF, and an MS in Health Care Management from Harvard School of Public Health.

---

## The Connect-One Study: What We Know

The Connect-One Early Feasibility Study has FDA approval and is being conducted at University of Michigan Health. Per the press release, the study is evaluating the Connexus BCI for its ability to safely restore speech and enable computer control for people living with severe motor impairment. The first human implantation was announced earlier in July 2026, shortly before this CCO appointment.

**What the source does not specify:** The press release does not disclose the NCT trial identifier, enrollment target, electrode count in the implanted array, or any preliminary signal quality or decoding accuracy data. Readers should treat all performance claims about the Connexus BCI as reflecting the company's technical design goals for an investigational device — no clinical efficacy or safety outcomes data from the Connect-One study is yet publicly available.

Paradromics describes the Connexus BCI as the "highest-data-rate brain-computer interface in the world," designed to capture neural activity at the resolution of individual neurons. The device targets translation of neural intent into speech, computer control, movement, and other motor functions. The company also describes a longer-term roadmap that includes direct AI interaction, advanced prosthetics, sensory feedback, and mental health applications — though none of these are under active FDA study at this time.

*Note: The Connexus BCI is an investigational device. It is not FDA-approved for commercial use. All clinical findings referenced here come from an ongoing feasibility study, not a controlled pivotal trial.*

---

## Industry Context: Why Clinical Leadership Hires Signal Inflection Points

Across the intracortical BCI field, the pattern is consistent: companies hire heavyweight clinical leadership when they are six to eighteen months from needing to present substantive feasibility data to the FDA and begin designing a pivotal trial. Neuralink brought in a Chief Medical Officer ahead of its PRIME Study enrollment expansion. [Synchron](https://bciintel.com/companies/synchron) built its clinical team in advance of its U.S. stentrode feasibility data readout.

For Paradromics, the Marks hire is the clearest signal yet that the company is not just running a first-in-human study to generate press — it is structuring itself to use Connect-One data as the foundation for a broader regulatory strategy. The explicit mandate Marks has been given — identifying the most logical clinical applications, designing products around patient and clinician needs, and building the evidence required for regulatory approval — reads like a De Novo or PMA preparation brief.

The neuromodulation-to-BCI analogy Marks himself invoked in the press release is analytically useful: DBS went from experimental to routine clinical care over roughly two decades. The BCI field is arguably compressing that timeline, but only if companies generate the kind of rigorous, independently verifiable clinical evidence that survives FDA review. The Marks hire is a bet that Paradromics intends to do exactly that.

For the broader intracortical BCI field, this hire also reflects an emerging talent pattern: clinical leaders with Class III implantable device experience — people who have already navigated IDE studies, PMA submissions, and post-market surveillance requirements — are becoming a critical and scarce resource as multiple companies simultaneously enter the clinical translation phase.

---

## Key Takeaways

- **Paradromics has appointed William J. Marks, Jr., MD, MS-HCM, as Chief Clinical Officer**, effective as of the July 7, 2026 announcement.
- Marks brings nearly three decades of experience spanning UCSF neurology faculty, Medtronic DBS clinical development (2004–2010), and Verily Life Sciences senior clinical leadership (2016–2023).
- His primary mandate is supporting the FDA-approved **Connect-One Early Feasibility Study** of the Connexus BCI at University of Michigan Health, which completed its first human implantation earlier in July 2026.
- The study targets speech restoration and computer control for people with severe motor impairment, with [Amyotrophic Lateral Sclerosis (ALS)](https://bciintel.com/glossary/als) patients as a primary population.
- **No clinical efficacy or safety data from Connect-One is yet publicly available.** The Connexus BCI remains an investigational device.
- The hire reflects a structural shift at Paradromics from engineering-phase to clinical-stage medical device company — a transition that typically precedes pivotal trial design and expanded regulatory engagement.
- Marks' dual background in Class III implantable device regulation (via Medtronic DBS) and technology-company clinical science (via Verily) is specifically suited to a BCI company building toward a PMA pathway.

---

## Frequently Asked Questions

**Who is William Marks and why does his background matter for Paradromics?**
William J. Marks, Jr., MD, MS-HCM, is a neurologist with nearly three decades of experience in clinical neuroscience and implantable medical devices. He served as a Professor of Neurology at UCSF for nearly two decades, as Consultant Medical Director for Medtronic's Deep Brain Stimulation business from 2004 to 2010, and in senior clinical leadership at Verily Life Sciences from 2016 to 2023. His Class III implantable device regulatory experience and tech-company clinical science background are directly applicable to Paradromics' path toward FDA approval for the Connexus BCI.

**What is the Paradromics Connect-One Early Feasibility Study?**
Connect-One is an FDA-approved Early Feasibility Study of the Connexus BCI, being conducted at University of Michigan Health. It is evaluating whether the device can safely restore speech and enable computer control for people with severe motor impairment. The first human implantation occurred in early July 2026. The study is at an early feasibility stage — not a pivotal trial — and no safety or efficacy outcomes data are yet publicly available.

**What is the Connexus BCI designed to do?**
Paradromics describes the Connexus BCI as an intracortical device designed to record neural activity at single-neuron resolution and translate neural intent into speech, computer control, and movement. The company's stated longer-term roadmap includes direct AI interaction, advanced prosthetics, sensory feedback, and neurological/mental health applications, though these are not currently under FDA study.

**How does this hire fit the broader intracortical BCI field?**
Multiple companies — including Neuralink, Synchron, and Precision Neuroscience — are simultaneously advancing first-in-human intracortical and ECoG BCI studies. Clinical leadership with Class III implantable device regulatory experience is becoming a scarce and strategically critical resource across the field as companies move from feasibility to pivotal trial design.

**Is the Connexus BCI approved for commercial use?**
No. The Connexus BCI is an investigational device, limited by U.S. law to investigational use. It is under evaluation in the Connect-One Early Feasibility Study and has not received FDA approval or clearance for commercial distribution.